KORRO BIO INC. - COMM

Korro to Participate in Upcoming Investor Conferences

21 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

21 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Korro to Present at the Jefferies London Healthcare Conference

14 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 Nov 2024 15:05:02 By Nasdaq GlobeNewswire

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

04 Nov 2024 06:25:00 By Nasdaq GlobeNewswire

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

30 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

16 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Korro to Participate in Upcoming Investor Conferences

10 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Korro to Participate in Upcoming September Investor and Scientific Conferences

27 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

13 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Korro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes

01 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Korro to Participate in Upcoming June Investor and Scientific Conferences

30 May 2024 15:01:00 By Nasdaq GlobeNewswire

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

20 May 2024 13:30:00 By Nasdaq GlobeNewswire

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

14 May 2024 15:01:00 By Nasdaq GlobeNewswire

Korro Announces $70 Million Private Placement

18 Apr 2024 07:30:59 By Nasdaq GlobeNewswire

Korro to Participate in Upcoming Investor Conferences

01 Apr 2024 15:01:00 By Nasdaq GlobeNewswire

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

26 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Korro to Present at the TD Cowen 44th Annual Health Care Conference

27 Feb 2024 07:00:01 By Nasdaq GlobeNewswire

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

18 Jan 2024 07:00:00 By Nasdaq GlobeNewswire